1.60
+5.26%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioRestorative Therapies
From its filings with the US Securities and Exchange Commission
BioRestorative Therapies is based in Melville, New York and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker BRTX. The SEC classifies its business as misc health & allied services, nec. In the fiscal year to 31 December 2025, it reported revenue of $359,700 and a net loss of $14.2m. At that date it held total assets of $4.1m and shareholders' equity of $356,744. By business, Product [Member] brought in 83.4% of revenue, followed by Royalty [Member] at 16.6%.
Patents related to the ThermoStem Program have been issued in the United States and other jurisdictions.
June 2025, we announced the hiring of Sandy Lipkins whose responsibilities focus on technology commercialization and business development.
October 2025, we announced that we hired Crystal Romano as our Head of Global Commercial Operations.
February 2026, we announced that we had completed the enrollment of 99 patients in our Phase 2 clinical trial of BRTX-100.
States patents, 18 foreign patents and one United States patent application related to research regarding our ThermoStem Program.
ATM and warrant exercises as well as through investment bankers and from biotech funds, strategic partners and other financial institutions.
April 2023, we announced that we had completed enrollment for the safety run-in component of our Phase 2 clinical study of BRTX-100.
June 2023, we announced that the final subject in our BRTX-100 Phase 2 clinical trial safety cohort had been dosed.
February 2026, we announced that we had completed the enrollment of 99 patients in our Phase 2 clinical trial of BRTX-100.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jul 2001
- Employees
- 6
- Website
- biorestorative.com ↗
- Head office
- 40 MARCUS DRIVE, MELVILLE, NY
- Incorporated in
- NV
- Classification
- Services-Misc Health & Allied Services, NEC
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Lance AlstodtChairman of the Board, President, Chief Executive Officer, since 2020$1.4m
- Mr. Robert KristalChief Financial Officer$683,752
- Mr. Francisco SilvaVice President - Research & Development, Secretary, Director, since 2013$1.2m
- Dr. Nickolay KukekovIndependent Director$125,000
- Mr. David RosaIndependent Director$125,000
- Mr. Patrick WilliamsIndependent Director$125,000
- Mr. Stephen KilmerInvestor Relations, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 6 full-time employees
- Operates in Biotechnology industry with a focus on cell and tissue protocols
- Develops therapeutic products using adult stem cells
Weaknesses
- Company has a small workforce of 6 employees
- IPO occurred in 2001, indicating a long history but potentially limited recent growth
- Company is developing multiple programs including Disc/Spine and Metabolic Programs
Opportunities
- BRTX-100 is being developed for non-surgical treatment of painful lumbosacral disc disorders
- ThermoStem is being developed for metabolic disorders including obesity and diabetes
- Proprietary technology used in BRTX-100 production process
Threats
- Company is a life sciences company with multiple development programs
- Development of cell-based therapies faces regulatory and clinical trial challenges
- Small company size may limit resources for research and development
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.